Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.83 |
| ▸ | EGFR | P00533 | 9/20 | 0.83 |
| ▸ | RET | P07949 | 6/20 | 0.83 |
| ▸ | KIF5B | P33176 | 6/20 | 0.83 |
| ▸ | FLT1 | P17948 | 10/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.66 |
| ▸ | FLT4 | P35916 | 6/20 | 0.64 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.64 |
| ▸ | RAF1 | P04049 | 2/20 | 0.61 |
| ▸ | BRAF | P15056 | 2/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.60 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.60 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.60 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.60 |
| ▸ | TEK | Q02763 | 2/20 | 0.60 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.60 |
| ▸ | PLK4 | O00444 | 1/20 | 0.60 |
| ▸ | CIT | O14578 | 1/20 | 0.60 |
| ▸ | GAK | O14976 | 1/20 | 0.60 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28007000 | 0.99 | KDR (0.81) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL5241456 | 0.95 | KDR (0.83) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL1781767 | 0.92 | KDR (0.71) | KDREGFRRETKIF5BFLT1 | |
| Trifluoroacetic Acid SCHEMBL29372105 | 0.92 | KDR (0.70) | KDREGFRRETKIF5BFLT1 | |
| Trifluoroacetic Acid SCHEMBL2089050 | 0.92 | KDR (0.70) | KDREGFRRETKIF5BFLT1 | |
| Trifluoroacetic Acid SCHEMBL28007015 | 0.91 | KDR (0.69) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL5864525 | 0.91 | KDR (1.00) | KDREGFRRETKIF5BFLT1 | |
| Hydrochloric Acid SCHEMBL7864775 | 0.90 | KDR (0.98) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL2055589 | 0.89 | RAF1 (0.76) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL1467058 | 0.88 | KDR (0.83) | KDREGFRRETKIF5BFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150317-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2024-05-09 | — | — | US | claimed |
| US-20220033377-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2022-02-03 | — | — | US | claimed |
| US-10457664-B2 | Quinazoline derivatives as VEGF inhibitors | GENZYME CORPORATION (US) | 2019-10-29 | — | — | US | claimed |
| US-10344015-B2 | Chemical process for the synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2019-07-09 | — | — | US | claimed |
| US-20180118716-A1 | Chemical Process | GENZYME CORPORATION (US) | 2018-05-03 | — | — | US | claimed |
| US-20160185754-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | ASTRAZENECA AB (SE) | 2016-06-30 | — | — | US | claimed |
| US-20140378684-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | ASTRAZENECA AB (SE) | 2014-12-25 | — | — | US | claimed |
| US-20120095229-A1 | CHEMICAL PROCESS | GENZYME CORPORATION | 2012-04-19 | — | — | US | claimed |
| EP-1943240-B1 | CHEMICAL PROCESS | ASTRAZENECA AB (SE) | 2009-11-11 | — | — | EP | claimed |
| US-20090203905-A1 | CHEMICAL PROCESS | GENZYME CORPORATION | 2009-08-13 | — | — | US | claimed |
| EP-1943240-A2 | CHEMICAL PROCESS | Astra Zeneca AB (SE) | 2008-07-16 | — | — | EP | claimed |
| WO-2007036713-A2 | CHEMICAL PROCESS | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | WO | claimed |
| US-20240150317-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2024025991-A1 | METHODS FOR DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION | THE METHODIST HOSPITAL SYSTEM (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20220033377-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2022-02-03 | — | — | US | disclosed |
| US-20220033377-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2022-02-03 | — | — | US | disclosed |
| EP-0929530-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1999-07-21 | — | — | EP | disclosed |
| EP-0885198-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-23 | — | — | EP | disclosed |
| WO-1998013354-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
| WO-1997032856-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378684-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | CYP3A4, CYP3A7, CYP4B1 | KDR 3217/4885EGFR 3838/4885RET 3472/4885 |
| US-10457664-B2 | Quinazoline derivatives as VEGF inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 179/4885RET 509/4885 |
| US-20220033377-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | CYP3A4, CYP3A7, CYP4B1 | KDR 3217/4885EGFR 3838/4885RET 3472/4885 |
| US-20090203905-A1 | CHEMICAL PROCESS | CYP3A4, CYP3A5, CYP3A7 | KDR 3543/4885EGFR 3879/4885RET 2751/4885 |
| US-20240150317-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | CYP3A4, CYP3A7, CYP4B1 | KDR 3217/4885EGFR 3838/4885RET 3472/4885 |
| US-20160185754-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | CYP3A4, CYP3A7, CYP4B1 | KDR 3217/4885EGFR 3838/4885RET 3472/4885 |
| US-10344015-B2 | Chemical process for the synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | CYP3A4, CYP3A7, CYP4B1 | KDR 3258/4885EGFR 3911/4885RET 3396/4885 |
| US-20120095229-A1 | CHEMICAL PROCESS | CYP3A4, CYP3A5, CYP3A7 | KDR 3543/4885EGFR 3879/4885RET 2751/4885 |
| US-20180118716-A1 | Chemical Process | CYP3A4, CYP3A5, CYP3A7 | KDR 3543/4885EGFR 3879/4885RET 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.